Company: BDRX
Filing Date: 2025-07-31
Form Type: 6-K
Source: 0001171843-25-004878
Chunk: 0

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-07-31
Form: 6-K
Chunk 0
---
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

<div align='center'>REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of July 2025

Commission File Number: 001-37652

Biodexa Pharmaceuticals PLC
(Translation of
registrant's name into English)

1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom
(Address of principal
executive office)</div>

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F
[ X ] Form 40-F [ ]

The information included in this report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the registration statements on Form S-8 (File No. 333-214969) and Form F-3 (File No. 333-233901) of the Company (including any prospectuses forming a part of such registration statements) and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

<div align='center'>SIGNATURES</div>

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its
behalf by the undersigned, thereunto duly authorized.

| Date: July 31, 2025 |     | Biodexa Pharmaceuticals PLC                      
 (Registrant)                                     
 /s/ Stephen Stamp                                |
|:--------------------|:----|:-------------------------------------------------|
|                     |     | Stephen Stamp                                    |
|                     |     | Chief Executive Officer, Chief Financial Officer |